• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 25
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 25
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    Hygienic Packaging Technology

    Trends in Solid Oral Dosage Delivery

    5 Reasons Paper Has No Place in Contract Manufacturing

    Injectable Drug Delivery Trends

    Pharmaceutical Manufacturing Equipment Trends
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    Amgen to Acquire Five Prime Therapeutics for $1.9B

    Genesis Drug Discovery & Development Acquires Integrated Analytical Solutions

    CureVac, Novartis Ink COVID Vax Mfg. Pact

    Innoforce and dMed Enter Development Collaboration

    Matica Biotechnology Breaks Ground on Cell and Gene Therapy Site
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    Reed-Lane Facility Virtual Tour

    CureVac, Novartis Ink COVID Vax Mfg. Pact

    Matica Biotechnology Breaks Ground on Cell and Gene Therapy Site

    WuXi AppTec Completes OXGENE Acquisition

    Trends in Solid Oral Dosage Delivery
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    Reed-Lane Facility Virtual Tour

    Hygienic Packaging Technology

    Reshaping the Pharmaceutical Supply Chain

    Serialization: Level 5 Solution

    Covectra Introduces Next-Gen Serialization Solution
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Genesis Drug Discovery & Development Acquires Integrated Analytical Solutions

    Innoforce and dMed Enter Development Collaboration

    Matica Biotechnology Breaks Ground on Cell and Gene Therapy Site

    Four Female Leaders Appointed to Cell & Gene CDMO

    Strata Oncology Unveils Strata PATH Trial
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    Guide to Maintaining Validation of Older Facilities: Why, When and How

    The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021

    Top BioPharma Form Accumulus Synergy

    Global Biosciences Co. Selects ValGenesis VLMS

    Gene Therapy Co. Selects ValGenesis' SaaS Platform
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    Reed-Lane

    Emergent BioSolutions

    Aphena Pharma Solutions

    Cytovance Biologics

    Almac Group
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    Baxter BioPharma Solutions

    Alcami

    Adare Pharma Solutions

    PCI Pharma Services

    Emergent BioSolutions
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • Podcasts
    • White Papers
    • Infographics
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Breaking News

    Fibrocell, Castle Creek Enter Collaboration

    To develop and commercialize Fibrocell’s lead gene therapy candidate, FCX-007, for the treatment of recessive dystrophic epidermolysis bullosa (RDEB)

    Related CONTENT
    • Mogene
    • Softweb Solutions
    • Pii Receives EIR From FDA
    • Catalent Enters Clinical Supply Partnership with Adial
    • Former FDA Senior Executives Join PAREXEL
    04.15.19
    Fibrocell Science, Inc. announced a collaboration agreement with Castle Creek Pharmaceuticals to develop and commercialize Fibrocell’s lead gene therapy candidate, FCX-007, for the treatment of recessive dystrophic epidermolysis bullosa (RDEB). 
     
    RDEB is a rare, life-threatening genetic disorder diagnosed at infancy with no cure or treatment approved by the U.S. Food and Drug Administration (FDA).

    “We are proud to partner with Castle Creek Pharmaceuticals, a company recognized for its innovation in drug development for rare skin diseases and its commitment to the epidermolysis bullosa community. This agreement provides resources and non-dilutive capital to continue the development and, if approved, commercialize FCX-007, a potentially transformative treatment for RDEB patients,” said John Maslowski, president and chief executive officer of Fibrocell. “With Castle Creek Pharmaceuticals providing funding for the development of FCX-007, Fibrocell can allocate additional resources to advance clinical development of FCX-013 for the treatment of moderate to severe localized scleroderma.”

    Under the terms of the collaboration agreement, Castle Creek Pharmaceuticals will receive an exclusive license to commercialize FCX-007 in the United States. Castle Creek Pharmaceuticals will be responsible for all development and manufacturing expenses up to $20 million prior to the initial Biologics License Application (BLA) filing with the FDA. If development spending exceeds $20 million, Castle Creek Pharmaceuticals will be responsible for 70% of the excess costs and Fibrocell will cover 30% of these additional expenses. Castle Creek Pharmaceuticals will also be responsible for all commercialization activities for FCX-007. Fibrocell will maintain responsibility for clinical development, regulatory interactions, and manufacturing of the product under a future supply agreement with Castle Creek Pharmaceuticals.  

    Fibrocell will receive an upfront payment of $7.5 million, $2.5 million for the first patient enrolled in the Phase 3 clinical trial and $30 million upon BLA approval and commercial readiness. Fibrocell is also eligible to receive up to $75 million in sales milestones, consisting of $25 million when FCX-007 achieves $250 million in cumulative net sales and an additional $50 million upon attaining $750 million in cumulative net sales. In addition, Castle Creek Pharmaceuticals will pay Fibrocell a 30% share of the gross profits from FCX-007 sales.

    “We believe our collaboration with Fibrocell is synergistic and serves both of our long-term objectives well. It increases the breadth of Castle Creek’s potential epidermolysis bullosa therapies by combining our clinical trial evaluating our investigational topical therapy (CCP-020) for epidermolysis bullosa simplex (EBS) with Fibrocell’s gene therapy to potentially treat RDEB,” said Greg Wujek, chief executive officer of Castle Creek Pharmaceuticals. “Castle Creek values the contributions of the Fibrocell team in progressing development of FCX-007, and we are excited to work with them to continue advancing this novel EB therapy that offers the potential to bring relief to patients suffering from this chronic, painful and debilitating disease.”
    Related Searches
    • it
    • fda
    • Manufacturing
    • chief executive officer
    Suggested For You
    Mogene Mogene
    Softweb Solutions Softweb Solutions
    Pii Receives EIR From FDA Pii Receives EIR From FDA
    Catalent Enters Clinical Supply Partnership with Adial Catalent Enters Clinical Supply Partnership with Adial
    Former FDA Senior Executives Join PAREXEL Former FDA Senior Executives Join PAREXEL
    Heritage Pharma Labs Bolsters Portfolio Heritage Pharma Labs Bolsters Portfolio
    CavoGene Appoints CEO CavoGene Appoints CEO
    Kamada Appoints R&D VP Kamada Appoints R&D VP
    WCG, Prudentia Enter Pharmacovigilance Alliance WCG, Prudentia Enter Pharmacovigilance Alliance
    CureVac Appoints CDO CureVac Appoints CDO
    PBI Launches Biopharma Contract Services Business PBI Launches Biopharma Contract Services Business
    Onconova Appoints CEO Onconova Appoints CEO
    FDA Approves MabPlex FDA Approves MabPlex's IND
    PAREXEL Launches Biotech Division PAREXEL Launches Biotech Division
    Recro Pharma Amends IV Meloxicam License Agreement with Alkermes Recro Pharma Amends IV Meloxicam License Agreement with Alkermes

    Related Breaking News

    • Bio News | Breaking News | Collaborations & Alliances | CRO News | Drug Development | Drug Discovery | Industry News | R&D
      Innoforce and dMed Enter Development Collaboration

      Innoforce and dMed Enter Development Collaboration

      Aims to accelerate the development of innovative therapeutics.
      Tim Wright, Editor, Contract Pharma 03.03.21

    • Breaking News | CRO News | Drug Discovery | Industry News | R&D
      Icon to Acquire PRA Health Sciences

      Icon to Acquire PRA Health Sciences

      Brings together two organizations to create a leading healthcare intelligence and clinical CRO.
      Charles Sternberg, Assistant Editor 03.01.21

    • Analytical Services | Breaking News | Drug Discovery | Facilities | Industry News | R&D
      CatSci Opens New Site in UK

      CatSci Opens New Site in UK

      Strengthens analytical capabilities with the opening of a secondary site in Dagenham backed by a $4.2 million investment.
      Tim Wright, Editor, Contract Pharma 02.25.21


    • Breaking News | Collaborations & Alliances | Drug Development | Industry News | Solid Dosage/Creams/Ointments
      Pfizer Partners with Medicines Manufacturing Innovation Center

      Pfizer Partners with Medicines Manufacturing Innovation Center

      To transform the formulation of oral solid dosage medicines.
      Tim Wright, Editor, Contract Pharma 02.25.21

    • Breaking News | Collaborations & Alliances | Drug Discovery | Industry News | Information Technology
      CrownBio & JSR Life Sciences Partner with Cambridge Quantum Computing

      CrownBio & JSR Life Sciences Partner with Cambridge Quantum Computing

      Will leverage quantum machine learning for novel cancer treatment biomarker discovery.
      Tim Wright, Editor, Contract Pharma 02.25.21

    • Breaking News | Drug Development | Industry News
      Cyprium, Sentynl Therapeutics Ink Asset Purchase Agreement

      Cyprium, Sentynl Therapeutics Ink Asset Purchase Agreement

      Sentynl acquires CUTX-101 Copper Histidinate for the treatment of Menkes disease for $20 million in upfront and regulatory milestones.
      Kristin Brooks 02.24.21


    • Biologics, Proteins, Vaccines | Breaking News | Drug Development | Industry News | Information Technology
      Pfizer Selects Seven Bridges to Support RNA Sequencing Data

      Pfizer Selects Seven Bridges to Support RNA Sequencing Data

      Seven Bridges will centralize and manage terabytes scRNASeq data, which provides detailed analysis of gene expression in individual cells.
      Kristin Brooks 02.24.21

    • Analytical Services | Bioanalytical Services | Breaking News | Chemistry | Facilities | Industry News | Laboratory Testing | R&D
      Almac Group Completes $7M R&D Center

      Almac Group Completes $7M R&D Center

      Significant expansion of biocatalysis, flow chemistry, and peptide capacity.
      Tim Wright, Editor, Contract Pharma 02.23.21

    • Breaking News | Drug Development | Promotions & Moves
      Aevitas Therapeutics Appoints President and CEO

      Aevitas Therapeutics Appoints President and CEO

      Dr. Markus Peters offers a 25-year track record of developing and commercializing orphan and specialty pharmaceuticals.
      Charles Sternberg, Assistant Editor 02.22.21


    • Breaking News | Collaborations & Alliances | Drug Development
      Lilly, Rigel Enter Exclusive CNS Development Collaboration

      Lilly, Rigel Enter Exclusive CNS Development Collaboration

      Lilly will pay $125 million upfront and up to $835 million in potential milestones for Rigel's lead RIPK1 inhibitor, R552.
      Kristin Brooks 02.18.21

    • Breaking News | R&D
      Wavelength Pharmaceuticals Acquires Majority Stake in Vanamali Organics

      Wavelength Pharmaceuticals Acquires Majority Stake in Vanamali Organics

      Further strengthens its drug substance manufacturing footprint and global supply chain.
      Charles Sternberg, Assistant Editor 02.18.21

    • Biologics, Proteins, Vaccines | Breaking News | Collaborations & Alliances | Drug Development
      Biomunex, Onward Ink Strategic Antibody Development Pact

      Biomunex, Onward Ink Strategic Antibody Development Pact

      Exclusive worldwide license and development agreement will leverage Biomunex' next gen bi- and multi-specific antibody platform in hematological malignancies.
      Kristin Brooks 02.16.21


    • APIs | Breaking News | Drug Development | Formulation Development | Industry News | Solid Dosage/Creams/Ointments
      Lonza Expands Solid Small Molecule Services

      Lonza Expands Solid Small Molecule Services

      To encompass all aspects of solid form screening and characterization of small molecule APIs.
      Kristin Brooks 02.16.21

    • Biologics, Proteins, Vaccines | Collaborations & Alliances | Drug Development
      Molecular Templates, BMS Enter Strategic Research Pact

      Molecular Templates, BMS Enter Strategic Research Pact

      Aims to discover and develop multiple therapies for specific oncology targets utilizing MTEM’s next-gen engineered toxin body (ETB) platform.
      Kristin Brooks 02.11.21

    • Bio News | Biologics, Proteins, Vaccines | Breaking News | Collaborations & Alliances | Drug Development | Industry News
      AbbVie, Caribou Ink CAR-T Collaboration

      AbbVie, Caribou Ink CAR-T Collaboration

      Leverages Caribou's next-generation CRISPR genome editing technology platform and AbbVie's antigen-specific binders.
      Tim Wright, Editor, Contract Pharma 02.10.21

    Trending
    • Catalent Acquires Delphi Genetics
    • BMS Expands Cell Therapy Manufacturing Capabilities
    • AbbVie Opts To Acquire Mitokinin
    • Four Female Leaders Appointed To Cell & Gene CDMO
    • WuXi AppTec Completes OXGENE Acquisition
    Breaking News
    • Amgen to Acquire Five Prime Therapeutics for $1.9B
    • Genesis Drug Discovery & Development Acquires Integrated Analytical Solutions
    • CureVac, Novartis Ink COVID Vax Mfg. Pact
    • Innoforce and dMed Enter Development Collaboration
    • Matica Biotechnology Breaks Ground on Cell and Gene Therapy Site
    View Breaking News >
    CURRENT ISSUE

    March 2021

    • Hygienic Packaging Technology
    • Trends in Solid Oral Dosage Delivery
    • 5 Reasons Paper Has No Place in Contract Manufacturing
    • Injectable Drug Delivery Trends
    • Pharmaceutical Manufacturing Equipment Trends
    • Oral Solids: Market & Technology Trends
    • Nutraceutical Manufacturing: Meeting the Challenges of Today, Planning for Tomorrow
    • 2021 Contract Manufacturing Survey
    • Small Molecule Development Trends
    • Challenges & Opportunities Facing Small & Emerging Biopharma Companies
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    IFT Transitions 2021 Annual Event to Digital Experience
    NY Federal Judge Enters Permanent Injunction Against Dietary Supplement Manufacturer
    Statins May Contribute to Vascular Calcification by Inhibiting Vitamin K-Dependent Proteins
    Coatings World

    Latest Breaking News From Coatings World

    Chromaflo Technologies Adds Benjamin Woeste as Territory Sales Manager
    Maroon Group Acquires Cary Company's Raw Materials, Specialty Chemicals Distribution Business
    Matt Fogel Named Mule-Hide's Territory Manager – Southern Virginia
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    EchoNous Expands Its Kosmos Hardware Platform
    Medtronic Begins Trial to Assess Novel Ablation Tech to Treat AFib
    Europe's Cross-Border Medtech Deal Activity Rises in Q4 2020
    Contract Pharma

    Latest Breaking News From Contract Pharma

    Amgen to Acquire Five Prime Therapeutics for $1.9B
    Genesis Drug Discovery & Development Acquires Integrated Analytical Solutions
    CureVac, Novartis Ink COVID Vax Mfg. Pact
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    Estée Lauder Establishes Equity and Engagement Center of Excellence
    L'Oreal On How It Will Shape Beauty's Future at Today's Transparency Summit
    C.O. Bigelow Earns Praise as NYC's Oldest Family-Run Apothecary
    Happi

    Latest Breaking News From Happi

    Avon Launches Vegan Skin Care Line
    Inolex Appoints VP Marketing
    Decorté Launches AI Diagnostics in US
    Ink World

    Latest Breaking News From Ink World

    Massilly North America Adds Koenig & Bauer MetalStar 3 Metal Decorating Press
    Hydrocarbon Solvents Market to Surpass $8.1 Billion by 2030
    Access Direct Mail Doubles Revenue with SCREEN's Truepress Jet520HD
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    Henkel publishes 30th Sustainability Report
    Avery Dennison Smartrac launches new Circus Pro inlays
    Springfield Solutions highlights digital label embellishments
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    FPInnovations Develops Biodegradable Mask
    Sani Professional Sanitizing and Disinfecting Products Approved by EPA
    Autefa Solutions Offers Fully Automated Line for Protective Mask Production
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    Bioventus Appoints Managing Director, China and Asia Pacific
    Full-Year Sales Down 12 Percent at Zimmer Biomet
    Lincotek Medical Expands Coatings and Additive Capacity
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    Comercial Kywi Improves Customer Service, Front-Store Operations with Zebra Mobile Solution
    Global Printed Circuit Board Market Projected to Reach $69.32 Billion by 2027
    Global Smart Glass Market to Register 6.8% CAGR Between 2021-28: Grand View Research

    Copyright © 2021 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login